Exaggerated Inflammatory Responses Mediated by Burkholderia Cenocepacia in Human Macrophages Derived from Cystic Fibrosis Patients

Overview

Journal Biochem Biophys Res Commun

Publisher Elsevier

Specialty Biochemistry

Date 2012 Jun 26

PMID 22728038

Citations 36

Authors

Benjamin T Kopp

Basant A Abdulrahman

Arwa A Khweek

Surender B Kumar

Anwari Akhter

Richard Montione

Mia F Tazi

Kyle Caution

Karen McCoy

Amal O Amer

Affiliations

Soon will be listed here.

Abstract

Cystic fibrosis (CF) is accompanied with heightened inflammation worsened by drug resistant Burkholderia cenocepacia. Human CF macrophage responses to B. cenocepacia are poorly characterized and variable in the literature. Therefore, we examined human macrophage responses to the epidemic B. cenocepacia J2315 strain in order to identify novel anti-inflammatory targets. Peripheral blood monocyte derived macrophages were obtained from 23 CF and 27 non-CF donors. Macrophages were infected with B. cenocepacia J2315 and analyzed for cytokines, cytotoxicity, and microscopy. CF macrophages demonstrated significant increases in IL-1β, IL-10, MCP-1, and IFN-γ production in comparison to non-CF controls. CF patients on prednisone exhibited globally diminished cytokines compared to controls and other CF patients. CF macrophages also displayed increased bacterial burden and cell death. In conclusion, CF macrophages demonstrate exaggerated IL-1β, IL-10, MCP-1, and IFN-γ production and cell death during B. cenocepacia infection. Treatment with corticosteroids acutely suppressed cytokine responses.

Citing Articles

Lipid A Structural Variants Induce Altered Immune Responses.

Hofstaedter C, OKeefe I, Met C, Wu L, Vanderwoude J, Shin S Am J Respir Cell Mol Biol. 2024; 71(2):207-218.

PMID: 38656811 PMC: 11299085. DOI: 10.1165/rcmb.2024-0059OC.

CFTR is required for zinc-mediated antibacterial defense in human macrophages.

Das Gupta K, Curson J, Tarique A, Kapetanovic R, Schembri M, Fantino E Proc Natl Acad Sci U S A. 2024; 121(8):e2315190121.

PMID: 38363865 PMC: 10895263. DOI: 10.1073/pnas.2315190121.

Resident macrophages of the lung and liver: The guardians of our tissues.

Kulle A, Thanabalasuriar A, Cohen T, Szydlowska M Front Immunol. 2022; 13:1029085.

PMID: 36532044 PMC: 9750759. DOI: 10.3389/fimmu.2022.1029085.

The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation.

Caverly L, Riquelme S, Hisert K Clin Chest Med. 2022; 43(4):647-665.

PMID: 36344072 PMC: 10224747. DOI: 10.1016/j.ccm.2022.06.007.

Cystic fibrosis transmembrane regulator correction attenuates heart failure-induced lung inflammation.

Uhl F, Vanherle L, Meissner A Front Immunol. 2022; 13:928300.

PMID: 35967318 PMC: 9365932. DOI: 10.3389/fimmu.2022.928300.

References

Levy H, Murphy A, Zou F, Gerard C, Klanderman B, Schuemann B . IL1B polymorphisms modulate cystic fibrosis lung disease. Pediatr Pulmonol. 2009; 44(6):580-93. PMC: 3716579. DOI: 10.1002/ppul.21026. View

van de Veerdonk F, Smeekens S, Joosten L, Kullberg B, Dinarello C, van der Meer J . Reactive oxygen species-independent activation of the IL-1beta inflammasome in cells from patients with chronic granulomatous disease. Proc Natl Acad Sci U S A. 2010; 107(7):3030-3. PMC: 2840365. DOI: 10.1073/pnas.0914795107. View

Abdulrahman B, Abu Khweek A, Akhter A, Caution K, Kotrange S, Abdelaziz D . Autophagy stimulation by rapamycin suppresses lung inflammation and infection by Burkholderia cenocepacia in a model of cystic fibrosis. Autophagy. 2011; 7(11):1359-70. PMC: 3359483. DOI: 10.4161/auto.7.11.17660. View

Ranganathan S, Parsons F, Gangell C, Brennan S, Stick S, Sly P . Evolution of pulmonary inflammation and nutritional status in infants and young children with cystic fibrosis. Thorax. 2011; 66(5):408-13. DOI: 10.1136/thx.2010.139493. View

Pillarisetti N, Williamson E, Linnane B, Skoric B, Robertson C, Robinson P . Infection, inflammation, and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med. 2011; 184(1):75-81. DOI: 10.1164/rccm.201011-1892OC. View

Jones A, Dodd M, Govan J, Barcus V, Doherty C, Morris J . Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax. 2004; 59(11):948-51. PMC: 1746874. DOI: 10.1136/thx.2003.017210. View

Govan J, Brown P, Maddison J, Doherty C, Nelson J, Dodd M . Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet. 1993; 342(8862):15-9. DOI: 10.1016/0140-6736(93)91881-l. View

Kotrange S, Kopp B, Akhter A, AbdElaziz D, Abu Khweek A, Caution K . Burkholderia cenocepacia O polysaccharide chain contributes to caspase-1-dependent IL-1beta production in macrophages. J Leukoc Biol. 2010; 89(3):481-8. PMC: 3040464. DOI: 10.1189/jlb.0910513. View

LiPuma J, Dasen S, Nielson D, Stern R, Stull T . Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet. 1990; 336(8723):1094-6. DOI: 10.1016/0140-6736(90)92571-x. View

10.

Saldias M, Ortega X, Valvano M . Burkholderia cenocepacia O antigen lipopolysaccharide prevents phagocytosis by macrophages and adhesion to epithelial cells. J Med Microbiol. 2009; 58(Pt 12):1542-1548. DOI: 10.1099/jmm.0.013235-0. View

11.

Akhter A, Gavrilin M, Frantz L, Washington S, Ditty C, Limoli D . Caspase-7 activation by the Nlrc4/Ipaf inflammasome restricts Legionella pneumophila infection. PLoS Pathog. 2009; 5(4):e1000361. PMC: 2657210. DOI: 10.1371/journal.ppat.1000361. View

12.

Soyza A, Ellis C, Khan C, Corris P, De Hormaeche R . Burkholderia cenocepacia lipopolysaccharide, lipid A, and proinflammatory activity. Am J Respir Crit Care Med. 2004; 170(1):70-7. DOI: 10.1164/rccm.200304-592OC. View

13.

Goodyear A, Jones A, Troyer R, Bielefeldt-Ohmann H, Dow S . Critical protective role for MCP-1 in pneumonic Burkholderia mallei infection. J Immunol. 2010; 184(3):1445-54. PMC: 2878842. DOI: 10.4049/jimmunol.0900411. View

14.

Bonfield T, Panuska J, Konstan M, Hilliard K, Hilliard J, Ghnaim H . Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med. 1995; 152(6 Pt 1):2111-8. DOI: 10.1164/ajrccm.152.6.8520783. View

15.

Armstrong D, Hook S, Jamsen K, Nixon G, Carzino R, Carlin J . Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr Pulmonol. 2005; 40(6):500-10. DOI: 10.1002/ppul.20294. View

16.

LaMothe J, Valvano M . Burkholderia cenocepacia-induced delay of acidification and phagolysosomal fusion in cystic fibrosis transmembrane conductance regulator (CFTR)-defective macrophages. Microbiology (Reading). 2008; 154(Pt 12):3825-3834. DOI: 10.1099/mic.0.2008/023200-0. View

17.

Kazachkov M, Lager J, Lipuma J, Barker P . Survival following Burkholderia cepacia sepsis in a patient with cystic fibrosis treated with corticosteroids. Pediatr Pulmonol. 2001; 32(4):338-40. DOI: 10.1002/ppul.1127. View

18.

Keith K, Hynes D, Sholdice J, Valvano M . Delayed association of the NADPH oxidase complex with macrophage vacuoles containing the opportunistic pathogen Burkholderia cenocepacia. Microbiology (Reading). 2009; 155(Pt 4):1004-1015. DOI: 10.1099/mic.0.026781-0. View

19.

Olland A, Falcoz P, Kessler R, Massard G . Should cystic fibrosis patients infected with Burkholderia cepacia complex be listed for lung transplantation?. Interact Cardiovasc Thorac Surg. 2011; 13(6):631-4. DOI: 10.1510/icvts.2011.271874. View

20.

Holden M, Seth-Smith H, Crossman L, Sebaihia M, Bentley S, Cerdeno-Tarraga A . The genome of Burkholderia cenocepacia J2315, an epidemic pathogen of cystic fibrosis patients. J Bacteriol. 2008; 191(1):261-77. PMC: 2612433. DOI: 10.1128/JB.01230-08. View